# US 8,784,820 B2 · Plasminogen-activating antibody, use and producing method thereof and agent including the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,784,820 B2
- Document ID: US8784820B2
- Status: Granted
- Kind: B2
- Application number: 13/668,052
- Filed: 2012-11-02
- Published: 2013-05-23
- Granted: 2014-07-22
- Earliest claimed: 2011-11-02
- Applicants: National Cheng Kung University
- Inventors: Trai-Ming Yeh; Yung-Chun Chuang
- Web page: https://patentgrep.com/patent/US8784820B2

## CPC

- C07K 16/18: against material from animals or humans
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C07K 16/108: Orthomyxoviridae (F), e.g. influenza virus
- C12N 9/0002: {Antibodies with enzymatic activity, e.g. abzymes}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

An antibody for activating plasminogen is provided. The antibody is produced from a hybridoma cell line deposited on Nov. 24, 2011 under accession number BCRC 960433 at Food Industry Research and Development Institute, 331 Shih-Pin Road, Hsinchu 300, Taiwan. The uses and producing method of the antibody, and an agent including the antibody used for treating stroke, myocardial infarction or syndromes cause by thrombus are also disclosed.

## Claims

### Claim 1

A plasminogen-activating antibody formed by hybridoma cell line, wherein the hybridoma cell line is deposited on Nov. 24, 2011 under accession number BCRC 960433 at the Food Industry Research and Development Institute, 331 Shih-Pin Road, Hsinchu 300, Taiwan and also on Nov. 14, 2013 under accession number DSM ACC3219 at Leibniz-Institut Dsmz-Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH, Inhoffenstr. 7B, D-38124 Braunschweig, Germany.

### Claim 2 (depends on 1)

The antibody according to claim 1, wherein the hybridoma cell line is fused by myeloma cells and Dengue virus immunolized splenocyte.

### Claim 3 (depends on 1)

The antibody according to claim 1, wherein the antibody has specificity for an amino acid sequence comprising at least Leu-Pro-X-Pro, and X is any amino acid residue.

### Claim 4 (depends on 1)

The antibody according to claim 1, wherein the antibody also comprises binding ability with dengue virus E protein and the plasminogen.

### Claim 5 (depends on 1)

The antibody according to claim 1, wherein the antibody activates the plasminogen by activity of the serine protease to form plasmin.

### Claim 6 (depends on 1)

The antibody according to claim 1, wherein the antibody acts with the activator of the plasminogen.

### Claim 7 (depends on 1)

An agent for treating stroke, myocardial infarction or syndromes caused by thrombus comprising the antibody according to claim 1.